自扩增mRNA新冠疫苗GRT-R910作为加强针的安全性、反应原性与免疫原性
一项开放标签、剂量递增的1期研究纳入了48名已完成新冠基础免疫或感染过的健康成人,评估自扩增mRNA疫苗GRT-R910作为加强针的安全性及免疫原性。结果显示该疫苗安全性良好但反应原性较高,17%的受试者出现严重全身反应;多数受试者的假病毒中和抗体几何平均倍数上升,且应答可持续至6个月。
要点
- GRT-R910加强针安全性可接受,但17%受试者出现严重全身反应。
- 多数受试者中和抗体几何平均倍数上升,应答持续至6个月。
- ≤60岁者3μg组第29天和第181天GMFR分别为5.2和6.1。
核心结论
- GRT-R910对既往接种或感染过的成人安全但反应原性较高,并在多数受试者中增强抗SARS-CoV-2中和抗体应答,应答可持续长达6个月。
研究设计与样本
- 开放标签、剂量递增1期研究,纳入完成基础新冠疫苗接种、加强接种或已知SARS-CoV-2感染后≥112天的健康成人48名。
- 18-60岁受试者接受3或6μg单剂GRT-R910(每组n=10);>60岁受试者接受3、6或10μg(每组n=8-10)。
- 接种后评估安全性及免疫原性达1年。
主要发现
- 多数受试者出现轻至中度全身反应和/或注射部位压痛,48名中8名(17%)出现严重全身反应。
- ≤60岁者第29天和第181天针对SARS-CoV-2(D614G)的假病毒中和抗体GMFR:3μg组分别为5.2(95%CI 2.1, 13.3)和6.1(2.8, 13.2);6μg组分别为3.6(1.3, 10.4)和2.4(0.2, 33.0)。
- >60岁者第29天和第181天GMFR:3μg组分别为8.1(2.1, 31.4)和8.2(1.2, 57.5);6μg组分别为2.7(1.1, 6.7)和1.8(0.5, 6.7);10μg组分别为3.3(1.5, 7.4)和3.3(1.3, 8.0)。
- ≤60岁6μg组及>60岁6μg和10μg组基线几何平均滴度较高,可能降低了这些组的GMFR。
- 多数组GMFR持续至第181天,表明加强接种与GMFR的持久升高相关;基于焦点减少中和试验的中和抗体滴度结果与假病毒中和试验 largely 一致。
临床怎么用
- 对于既往接种或感染过新冠的成人,GRT-R910可作为加强候选,但需权衡其较高的反应原性。
- 接种后应关注严重全身反应,尤其需向受试者说明17%的发生率。
- 中和抗体应答可持续6个月,支持其作为加强针的免疫持久性优势。
局限性
- 开放标签设计可能引入偏倚。
- 样本量小(48人),各剂量组仅8-10人。
- 基线中和抗体滴度较高可能低估部分组的GMFR。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: GRT-R910 (Gritstone bio, Inc), a self-amplifying mRNA vaccine expressing SARS CoV-2 (D614G) spike protein and T-cell epitopes, was evaluated as a booster vaccine in a phase 1 study in 2021-2022. METHODS: This open-label, dose escalation study enrolled healthy adults ≥112 days after completion of primary COVID-19 vaccination, booster of approved mRNA COVID-19 vaccine, or known SARS-CoV-2 infection. Persons aged 18-60 years received single doses of 3 or 6 μg GRT-R910 (n = 10/group). Persons >60 years of age received GRT-R910 at 3, 6, or 10 μg (n = 8-10/group). Safety and immunogenicity responses were assessed for 1 year after vaccination. RESULTS: We enrolled 48 participants. Most participants developed mild-to-moderate systemic reactions and/or injection site tenderness. Eight of 48 (17%) had severe systemic reactions. Pseudovirus neutralizing antibody geometric mean fold rise (GMFR) responses against SARS-CoV-2 (D614G) at Day 29 and Day 181, respectively, among those ≤60 years were 5.2 (95% CI 2.1, 13.3) and 6.1 (2.8, 13.2) after 3 μg, and 3.6 (1.3, 10.4) and 2.4 (0.2, 33.0) after 6 μg. The GMFR responses among those aged >60 years were 8.1 (2.1, 31.4) and 8.2 (1.2, 57.5) after 3 μg, 2.7 (1.1, 6.7) and 1.8 (0.5, 6.7) after 6 μg, 3.3 (1.5, 7.4) and 3.3 (1.3, 8.0) after 10 μg. The 6 μg dose group in those ≤60 years, 6 μg and 10 μg dose groups in those aged >60 years had higher baseline geometric mean titers (GMTs), which, in turn may have lowered the GMFR for those groups. GMFR persistence until Day 181 in most groups indicated these boosts were associated with durable increases in GMFR. Neutralizing antibody titers assessed via focus reduction neutralization test against SARS-CoV-2 D614G largely mirrored the PsVNA findings. CONCLUSIONS: GRT-R910 was safe but reactogenic when administered to previously vaccinated or infected adults and boosted anti-SARS-CoV-2 neutralizing antibody responses in most participants with responses that appeared durable for up to 6 months. CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/study/NCT04776317. CLINICALTRIALS: gov ID NCT04776317.
引用
- Whitaker JA, Rebolledo PA, Abate G, et al. The safety, reactogenicity, and immunogenicity of the self-amplifying mRNA COVID-19 vaccine GRT-R910 as a booster in healthy adults. Vaccine. 2026. PMID: 41740461. doi:10.1016/j.vaccine.2026.128358
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。